Antibodies against GPR64 and uses thereof

Details Antibodies against GPR64 and uses thereof Antibodies against GPR64 and uses thereof

2008-09-03

2010-10-05

Rawlings, Stephen L (Department: 1643)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Structurally-modified antibody, immunoglobulin, or fragment...

C435S069100, C435S328000, C435S330000, C435S331000, C435S334000, C435S375000, C530S350000, C530S387300, C530S387700, C530S387900, C530S388220, C530S391300, C530S391700, C424S135100, C424S138100, C424S139100, C424S143100, C424S155100, C424S174100, C424S181100, C424S183100

Reexamination Certificate

active

07807163

ABSTRACT:
GPR64 antibody compositions are provided. These antibodies may be used for diagnosis or treatment of cancer, especially ovarian cancer, Ewing's sarcoma, uterine cancer, and other GPR64 expressing tumor types.

REFERENCES:
patent: 6183968 (2001-02-01), Bandman
patent: 2002/0142951 (2002-10-01), Webster
patent: 2003/0138793 (2003-07-01), Su et al.
patent: 2004/0005563 (2004-01-01), Mack
patent: 2006/0069239 (2006-03-01), Kirchhoff et al.
patent: 19617940 (1997-10-01), None
patent: 0 805 204 (1997-11-01), None
patent: 1 033 401 (2000-09-01), None
patent: WO 98/45436 (1998-10-01), None
patent: WO 00/34473 (2000-06-01), None
patent: WO 00/56881 (2000-09-01), None
patent: WO 01/54477 (2001-08-01), None
patent: WO 01/70979 (2001-09-01), None
patent: WO 02/10449 (2002-02-01), None
patent: WO 02/061087 (2002-08-01), None
patent: WO 02/079406 (2002-10-01), None
patent: WO 02/083856 (2002-10-01), None
patent: WO 02/102235 (2002-12-01), None
patent: WO 02101357 (2002-12-01), None
patent: WO 03/038129 (2003-05-01), None
patent: WO 03/051925 (2003-06-01), None
patent: WO 03/071272 (2003-08-01), None
patent: WO 2004037860 (2004-05-01), None
Kirchoff et al. (Reproduction. Aug. 2008;136(2):235-45).
Fredriksson R., et al., “Novel Human G Protein-Coupled Receptors with Long N-Terminal Containing GPS domains and Ser/Thr-Rich Regions” FEBs Letters 531 p. 407-414 (2002).
Obermann et al., “HE6, a Two-Subunit Heptahelical Receptor Associated with Apical Membranes of Efficient Epididymal Duct Epithelia,” Molex. Reprod. & Develp. 64 : 13-26 (2003).
Gilewski et al., “Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21,” Clin. Cancer Res. 6 :1693-1701 (2000).
Scholl et al., “Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer,” J. Immunother, 23 :570-580 (2000).
Bon et al., “Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays,” Clin. Chem. 43 :585-593 (1997).
Fitzgibbons et al., “Prognostic factors in breast cancer, College of American Pathologiests Consensus Statement 1999,” Arch. Pathol. Lab. Med. 124 :966-978 (2000).
Hamilton and Piccart, “The contribution of molecular markers to the prediction of response in the treatment of breast cancer : a review of the literature on HER-2, p53 and BCL-2,” Ann. Oncol. 11 :647-663 (2000).
Fredriksson R., et al., “Novel human G protein-coupled receptors with long N-terminal containing GPS domains and Ser/Thr-rich regions,” FEBs Letters 531:407-414 (2002).
GenBank accession X81892 (1996).
GenBank accession CAA57479 (1996).
Doronina et al., “Development of potent monoclonal antibody auristatin conjugates for cancer therapy,” Nature Biotech, 21(7):778-784 (Jul. 2003).
Delphion Record for EP0805204B1 (Nov. 2006).
Toki et al., “Cures and regressions of established tumor xenografts with monoclonal antibody auristatin E conjugates,” ACS National Meeting, No. 223rd, p. 1, abstract (Apr. 7, 2002).
Robson, “Are BRCA1- and BRCA2-associated breast cancers different ? Prognosis of BRCA1-associated breast cancer,” J. Clin. Oncol. 18 (21 Suppl) : 113S-118S (2000).
George, et al.,“Differential Effects of Anti-Beta2-Glyprotein I Antibodies on ENdothelial Cells and on the Manifestations of Experimental Antiphospholipid Syndrome” Circulation, 97:900-906 (1998).
Bhaskar, V., et al.,“E-Selectin Up-Regulation Allows for Targeted Drug Delivery in Prostate Cancer,” Cancer Research 63:6387-6394 (2003).
Gottwald, et al. “New Approaches for Male Fertility Control: HE6 as an example of a Putative Target,” Mol. Cell. Endocrinal. 250:49-57 (2006).
Kirchhoff, et al.,“Role of Epididymal Receptor HE6 in the Regulation of Sperm Microenvironment,” Mol. Cell. Endocrinol. 250:43-48 (2006).
Greenspan, et al., “Defining epitopes: It's not as easy as it seems,” Nature Biotechnology, 17:936-937 (1999).

Affiliated with

Also associated with

Rating

Antibodies against GPR64 and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies against GPR64 and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies against GPR64 and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4214339